Ligand Pharmaceuticals Files 8-K on Financials
Ticker: LGNZZ · Form: 8-K · Filed: Aug 7, 2025 · CIK: 886163
| Field | Detail |
|---|---|
| Company | Ligand Pharmaceuticals Inc (LGNZZ) |
| Form Type | 8-K |
| Filed Date | Aug 7, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, operations
Related Tickers: LGND
TL;DR
LGND filed an 8-K on Aug 7, 2025, detailing financial results. Check it out.
AI Summary
Ligand Pharmaceuticals Inc. filed an 8-K on August 7, 2025, reporting on its Results of Operations and Financial Condition. The filing includes financial statements and exhibits, with the company's principal executive offices located in Jupiter, Florida.
Why It Matters
This 8-K filing provides an update on Ligand Pharmaceuticals' financial condition and operational results, which is crucial information for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any significant new risks or negative developments.
Key Players & Entities
- LIGAND PHARMACEUTICALS INC (company) — Registrant
- August 7, 2025 (date) — Date of Report
- Jupiter, Florida (location) — Principal executive offices
- Delaware (location) — State of incorporation
- 77-0160744 (identifier) — I.R.S. Employer Identification No.
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Ligand Pharmaceuticals Inc.'s Results of Operations and Financial Condition, including financial statements and exhibits.
When was this 8-K report filed?
This 8-K report was filed on August 7, 2025.
Where are Ligand Pharmaceuticals Inc.'s principal executive offices located?
Ligand Pharmaceuticals Inc.'s principal executive offices are located at 555 Heritage Drive, Suite 200, Jupiter, Florida 33458.
What is the company's state of incorporation?
The company's state of incorporation is Delaware.
What is the Registrant's telephone number?
The Registrant's telephone number is (858) 550-7500.
Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-08-07 07:04:26
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share LGND The Nasdaq Global Market
Filing Documents
- lgnd-20250807.htm (8-K) — 25KB
- q22025earningsrelease_ex991.htm (EX-99.1) — 213KB
- newligandlogo.jpg (GRAPHIC) — 11KB
- 0000886163-25-000047.txt ( ) — 390KB
- lgnd-20250807.xsd (EX-101.SCH) — 2KB
- lgnd-20250807_lab.xml (EX-101.LAB) — 21KB
- lgnd-20250807_pre.xml (EX-101.PRE) — 12KB
- lgnd-20250807_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 7, 2025, Ligand Pharmaceuticals Incorporated (the "Company") issued a press release announcing its financial results for the three and six months ended June 30, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated August 7, 2025.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIGAND PHARMACEUTICALS INCORPORATED Date: August 7, 2025 By: /s/ Andrew Reardon Name: Andrew Reardon Title: Chief Legal Officer and Secretary